DETAILED ACTION
Notice of Pre-AIA or AIA Status
The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA .
Status of Application/Amendment/Claims
Claims 21-32 and 35-40 filed 12/6/2024 are pending and are the subject of the present Official action.
Information Disclosure Statement
The information disclosure statement (IDS) submitted on 10/18/2024 was received. The submission was in compliance with the provisions of 37 CFR 1.97. Accordingly, the information disclosure statement was considered by the examiner.
Claim Objections
Claim 27 is objected to for missing “vector” when describing the composition of claim 21.
Claim 36 describes the vector used for treatment according to “any one of claim 35”. It appears that applicant is making an improper multiple dependent claim reference however singularly references claim 35. Thus, claim 36 is objected for using this improper terminology.
Claim Rejections - 35 USC § 112b
The following is a quotation of 35 U.S.C. 112(b):
(b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention.
The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph:
The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.
Claims 26, 28, 37-39 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor, or for pre-AIA the applicant regards as the invention.
Claim 26 describes the vector as an AAV9 or AAV10 “such as” AAVrh.10 “preferably” an AAVrh.10. Similarly, claims 28, 37 and 39 use the exemplary language “such as” and “preferably” when describing the vector embodiments and administration sites. A description of examples or preferences is properly set forth in the specification rather than the claims. If stated in the claims, examples and preferences may lead to confusion over the intended scope of a claim, see MPEP 2173.05(d). As a result, one of ordinary skill in the art would not understand if the listed vectors and administration sites are required to be accumulated or are merely exemplary in nature. Claim 38 is rejected for its dependency on indefinite claim 37.
Claim Interpretation
Claims 38 and 39 describe the vector for treating polyglutamine repeat spinocerebellar ataxia “which is to be administrated”. The claims recite limitations which are not required and are only prophetic in nature.
Claim Rejections - 35 USC § 103
In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status.
The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action:
A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made.
This application currently names joint inventors. In considering patentability of the claims the examiner presumes that the subject matter of the various claims was commonly owned as of the effective filing date of the claimed invention(s) absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and effective filing dates of each claim that was not commonly owned as of the effective filing date of the later invention in order for the examiner to consider the applicability of 35 U.S.C. 102(b)(2)(C) for any potential 35 U.S.C. 102(a)(2) prior art against the later invention.
Claims 21-32 and 35-40 are rejected under 35 U.S.C. 103 as being unpatentable over Caboche et al. US 2013/0209410, published 8/15/2013 (hereinafter Caboche) in view of Fan et al. "Polyglutamine (PolyQ) diseases: genetics to treatments." Cell transplantation 23.4-5 (2014): 441-458 (hereinafter Fan).
Claims 21-23, 30-32 and 40: Caboche describes a vector for the treatment of Huntington’s disease (HD), wherein the vector expresses cholesterol 24-hydroxylase (CYP46A1) in cells of the central nervous system (Caboche, para 3). Caboche provides a full description of the CYP46A1 gene, which encodes for cholesterol 24-hydroxylase (Caboche, Genbank Access Number AF094480, para 11). Caboche provides an overview of HD and the molecular markers of the disease. Caboche states that the mutation responsible for HD can be attributed to an unstable expansion of CAG repeat sequences located at the 5’ terminal part of the IT5 gene encoding the Huntingtin (htt) protein resulting in various cognitive impairments (Caboche, para 2). Caboche observed that CYP46A1, which encodes for an enzyme responsible for the degradation of cholesterol in the central nervous system, was neuroprotective in cellular and animal models of HD (Caboche, para 3). Thus, Caboche engineered vectors for the targeted expression of CYP46A1 in cells of the central nervous system as a treatment for HD. Caboche does not describe the treatment of polyglutamine repeat spinocerebellar ataxia of the type SCA1, SCA2, SCA3, SCA6, SCA7, SCA17 as recited in claims 21-23.
Claims 24-26 and 35-37: Caboche provides embodiments wherein the vector used include adenoviral, lentiviral, herpesvirus and adeno-associated viral (AAV) vectors (Caboche, para 19). Caboche provides express examples wherein the AAV vectors are serotypes AAV9, AAV10 and AAVrh.10 (Caboche, para 22, 66-68 and claim 18).
Claims 27-29 and 38-39: Caboche describes administration routes wherein the vectors are directly injected (intrathecal or intravenous) into various brain regions of the patient including the striatum, frontal lobe, brainstem, cerebellum and spinal cord (Caboche, para 37 and 39). Caboche describes administering a therapeutically effective amount of the vector to the patient (Caboche, para 48-50).
Claims 21-23, 30-32 and 40: Fan provides a review of a group of neurodegenerative disorders caused by expanded CAG repeats encoding a long polyglutamine (polyQ) tract in their respective proteins. Fan categorizes these diseases as “polyQ diseases” and lists a total of nine related disorders including six spinocerebral ataxias (SCA type diseases; SCA1, SCA3, SCA6, SCA7, SCA17), Machado-Joseph disease (MJD/SCA3) and Huntington’s disease (HD) among others (Fan, abstract). Fan outlines the molecular mechanisms of these polyQ diseases in which the expanded CAG repeats are translated into a series of uninterrupted glutamine residues forming a polyQ tracts, resulting in the accumulation of polyQ proteins which impair and damage the mitochondria, chaperone and ubiquitin proteasome systems resulting in neuron degeneration within the cerebellum, brainstem and spinal tract. Therefore, all of the polyQ diseases share similar molecular mechanisms wherein different dysfunctional polyQ tract-containing proteins ultimately lead to the degeneration of specific neural populations (Fan, Intro para 1, Table 1, spinocerebral ataxia pg 442 and HD pg 445).
It would have been prima facie obvious to one of ordinary skill in the art to use the viral vector encoding CYP46A1 as described by Caboche as a treatment for the various spinocerebral ataxias (SCA1, SCA3, SCA6, SCA7, SCA17) described by Fan since Caboche demonstrated this therapy as an effective treatment for HD, which is a closely related polyQ disease. Therefore, it would have been a matter of combining prior art elements according to known methods to yield predictable results given the close similarity of SCA and HD. One would have been motivated to make this combination in order to express CYP46A1 in targeted cells of SCA patients to serve as a neuroprotective treatment for dysfunctional polyQ tract-containing proteins implicated in SCA. One would have a reasonable expectation of success given the similarity of SCA and HD diseases as well as the similar routes of administration. Accordingly, in the absence of evidence to the contrary, one of ordinary skill in the art would have considered the claimed invention to have been prima facie obvious to at the time the invention was made.
Nonstatutory Double Patenting
The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Langi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).
A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on nonstatutory double patenting provided the reference application or patent either is shown to be commonly owned with the examined application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717 .02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP 706.02(1)(1) - 706.02(1)(3) for applications not subject to examination under the first inventor to file provisions of the AIA . A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b).
The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/patent/patents-forms. The filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA /25, or PTO/AIA /26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to www.uspto.gov/patents/process/file/efs/guidance/eTD-info-I.jsp.
Claims 21-32 and 35-40 are rejected on the grounds of nonstatutory double patenting as being unpatentable over claims 1-14 of US Patent No. US 12,138,298 (application number 16/480,541). Although the claims at issue are not identical, they are not patentably distinct from each other because the patented claims would anticipate the instant claims if they were available as prior art.
Claims 21-23, 30-32 and 40: The patented claims are drawn to a method for treating various spinocerebral ataxias (SCA1, SCA3, SCA6, SCA7, SCA17) comprising administering a vector which comprises cholesterol 24-hydroxylase (Claim 1).
Claims 24-26 and 35-37: The patented claims describe the use of AA9, AAV10 and AAVrh.10 vectors for delivery (Claims 7-9).
Claims 27-29 and 38-39: The patented claims describe administration directly into the brain, spinal cord and cerebellum.
The patented claims would anticipate the instantly claimed invention, which is drawn to the vector composition which is administered in the patented claims. The claim sets are patentable indistinct therefore.
Conclusion
No claims allowed.
Any inquiry concerning this communication or earlier communications from the examiner should be directed to Dr. ALEXANDER NICOL whose telephone number is (571)272-6383. The examiner can normally be reached on M-F 8-5 EST.
Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice.
If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Maria Leavitt can be reached on (571)272-1085. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.
Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see https://ppair-my.uspto.gov/pair/PrivatePair. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.
Alexander Nicol
Patent Examiner
Art Unit 1634
/ALEXANDER W NICOL/Examiner, Art Unit 1634